ASSEMBLY BIOSCIENCES, INC. (ASMB) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US0453962070

Price
21.79 USD
Market cap
443.66 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

ASSEMBLY BIOSCIENCES, INC. financials

Fiscal year2025
Revenue72.30 m USD
Operating income-12.12 m USD
EBIT-6.12 m USD
Net income-6.12 m USD
Diluted EPS – continuing operations-0.55 USD

Full history since 2008, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About ASSEMBLY BIOSCIENCES, INC.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 09.11.2026. Details in the risk notice.